普米克都保联合沙丁胺醇对咳嗽变异性哮喘患儿的疗效分析

目的:探讨普米克都保联合沙丁胺醇对咳嗽变异性哮喘(CVA)患儿的疗效分析。方法:选取100例CVA患者,沙丁胺醇组(48例)给予沙丁胺醇联合用药组(52例)给予沙丁胺醇和普米克都保,观察并记录两组患者治疗后的疗效,咳嗽缓解及消失时间,治疗前后的用力肺活量(FVC),第1秒用力呼气容积(FEV1)、呼气峰流速(PEF)及最大呼气中段流速(MMEF)等肺功能指标及随访1个月期间的不良反应,评价普米克都保联合沙丁胺醇对咳嗽变异性哮喘的疗效。结果:治疗后联合用药组有效率明显高于沙丁胺醇组(P0.05),联合用药组中有92.3%患者,沙丁胺醇组有72.9%患者咳嗽症状在2周内消失,治疗后联合用药组咳嗽缓解时间和消失时间明显短于沙丁胺醇组(P0.05)。治疗前后,两组在FVC,FEVl,PEF上相比,差异没有统计学意义(P0.05),治疗前,两组MMEF水平均明显低于体检健康者(P0.05),其他肺功能指标与体检健康者相比,无统计学差异(P0.05)。治疗后联合用药组MMEF明显高于治疗前,且高于沙丁胺醇组(P0.05)。沙丁胺醇组治疗前后MMEF未出现明显变化(P0.05)。随访1个月期间,两组不良反应率相比,差异没有统计学意义(P0.05)。结论:普米克都保联合沙丁胺醇能对CVA具有较好的治疗作用,能缩短咳嗽症状消失时间,改善患儿肺功能,值得临床推广使用。

Efficacy of Pulmicort Turbuhaler Combined with Salbutamol in the Treatment of Children with Cough Variant Asthma

Objective:To discuss the efficacy of Pulmicort Turbuhaler combined with salbutamol in the treatment of children with cough variant asthma.Methods:100 patients with cough variant asthma were selected and divided into two groups. The salbutamol group (48 cases) were given salbutamol, and the combination group(52 cases) were given salbutamol and Pulmicort Turbuhaler. The efficacy of Pulmicort Turbuhaler combined with salbutamol in the treatment of children with cough variant asthma were evaluated by efficacy, cough relief and disappearance time, FVC, FEV1, PEF, MMEF and adverse reactions during 1 month follow-up.Results:After treatment, the efficiency of combination group was higher than that of the salbutamol group. The cough symptoms disappeared within 2 weeks in 92.3%patients of combination group and 72.9%cases in combination group. After treatment, the cough relief and disappearance time of combination group was shorter than that of the salbutamol group (P<0.05). There were no statistical significance on FVC, FEV1, PEF between two groups (P>0.05). Before treatment, the MMEF of two groups were lower than that of the healthy children (P<0.05). Compared with the healthy children, the other lung function indexes of two groups were not statistically significant (P>0.05). After treatment, the MMEF of combination group was higher than the value before treatment and the value in the salbutamol group (P<0.05). During 1 month follow-up, there were no statistical significance in the incidence of adverse reactions between two groups (P>0.05).Conclusion:Pulmicort Turbuhaler combined with salbutamol have good effect on CVA, which can shorten the disappearance time of cough symptoms and improve the pulmonary function of children, worthy of clinical use.